ArticleActa pharmaceutica Sinica. B2022

Chemical screen identifies shikonin as a broad DNA damage response inhibitor that enhances chemotherapy through inhibiting ATM and ATR.

Fangfang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.